Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis
A live, multi-source view of Ginkgo Bioworks Holdings, Inc. (DNA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization.
Sector: Healthcare · Industry: Biotechnology · United States · 485 employees · ginkgo.bio
Key statistics · as of 2026-09-05
As of 2026-09-05, Ginkgo Bioworks Holdings, Inc. (DNA) had a market capitalization of $468.0M (forward -2.4) and a beta of 1.77; the shares traded in a 52-week range of $5.37 – $17.58 (-37.9% over the year).
- Market cap
- $468.0M
- Enterprise value
- $570.0M
- Forward P/E
- -2.4
- Price / book
- 1.05
- EPS (trailing)
- $-5.33
- EPS (forward)
- $-2.90
- Payout ratio
- 0.0%
- 52-week range
- $5.37 – $17.58
- 52-week change
- -37.9%
- Beta
- 1.77
- Average volume
- 1.1M
- Shares outstanding
- 55.4M
- Short % of float
- 10.43%
- Profit margin
- -219.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Ginkgo Bioworks Holdings, Inc. (DNA) last closed at $6.78 (the last completed close before that scan).
Technicals at the scan: RSI 42 (neutral territory), price -3.6% versus its 20-day average, 20-day versus 50-day average spread -11.2%, MACD histogram 0.02.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of DNA; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-25). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Steven P. Coen (0B/1S). Who is trading what
RapidTradeView pick record
DNA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Ginkgo Bioworks Holdings, Inc. (DNA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell DNA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.